Lung cancer patients harboring epidermal growth factor receptor mutation among those infected by human immunodefciency virus

OncoTargets and Therapy

Volumn 8, Issue , 2014, Pages 111-115

  Okuma, Yusuke ^a   Hosomi, Yukio ^a   Imamura, Akifumi ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Antiretroviral therapy; Epidermal growth factor receptor mutation; Human immunodefciency virus; Non AIDS defning cancers; Non small cell lung cancer

Indexed keywords

DARUNAVIR; DOCETAXEL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PEMETREXED; RALTEGRAVIR;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTIVIRAL THERAPY; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CD4 LYMPHOCYTE COUNT; CHEMORADIOTHERAPY; DRUG TREATMENT FAILURE; EGFR GENE; EXON; FRACTURE; FRACTURE TREATMENT; GENE DELETION; GENE MUTATION; HERPES ZOSTER; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG CANCER; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; RASH; TREATMENT DURATION; VIRUS LOAD;

EID: 84920487571     PISSN: 11786930     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S76712     Document Type: Article

References (26)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunode-fciency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337(11):725–733.
2. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337(11):734–739.
3. Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011; 103(9):753–762.
4. Sepkowitz KA. AIDS – the frst 20 years. N Engl J Med. 2001;344(23): 1764–1772.
5. Pakkala S, Ramalingam SS. Lung cancer in HIV-positive patients. J Thorac Oncol. 2010;5(11):1864–1871.
6. Sanchez X, Cousins-Hodges B, Aguilar T, et al. Activation of HIV-1 coreceptor (CXCR4) mediates myelosuppression. J Biol Chem. 1997;272(44):27529–27531.
7. Mitsudomi T, Morita S, Yatabe Y, et al. Geftinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121–128.
8. Maemondo M, Inoue A, Kobayashi K, et al. Geftinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–2388.
9. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353(2):123–132.
10. Shah NT, Kris MG, Pao W, et al. Practical management of patients with non-small-cell lung cancer treated with geftinib. J Clin Oncol. 2005;23(1):165–174.
11. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–967.
12. Burns DN, Hillman D, Neaton JD, et al. Cigarette smoking, bacterial pneumonia, and other clinical outcomes in HIV-1 infection. Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defc Syndr Hum Retrovirol. 1996;13(4):374–383.
13. Niaura R, Shadel WG, Morrow K, et al. Human immunodefciency virus infection, AIDS, and smoking cessation: the time is now. Clin Infect Dis. 2000;31(3):808–812.
14. Hughes JR. Treatment of smoking cessation in smokers with past alcohol/drug problems. J Subst Abuse Treat. 1993;10(2):181–187.
15. Erickson TM, Koeppe JR, Miller YE, Stuart RW, Camidge DR. Bron-chioloalveolar carcinoma presenting as chronic progressive pulmonary infltrates in a woman with HIV: a diagnosis worth making. J Thorac Oncol. 2008;3(11):1353–1355.
16. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS. 2006;20(12):1645–1654.
17. Herida M, Mary-Krause M, Kaphan R, et al. Incidence of non-AIDS-defning cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodefciency virus-infected patients. J Clin Oncol. 2003;21(18):3447–3453.
18. Hakimian R, Fang H, Thomas L, et al. Lung cancer in HIV-infected patients in the era of highly active antiretroviral therapy. J Thorac Oncol. 2007;2(4):268–272.
19. Lavole A, Chouaid C, Baudrin L, et al. Effect of highly active antiret-roviral therapy on survival of HIV infected patients with non-small-cell lung cancer. Lung Cancer. 2009;65(3):345–350.
20. Hooker CM, Meguid RA, Hulbert A, et al. Human immunodefciency virus infection as a prognostic factor in surgical patients with non-small cell lung cancer. Ann Thorac Surg. 2012;93(2):405–412.
21. Makinson A, Pujol JL, Le Moing V, Peyriere H, Reynes J. Interactions between cytotoxic chemotherapy and antiretroviral treatment in human immunodefciency virus-infected patients with lung cancer. J Thorac Oncol. 2010;5(4):562–571.
22. Wang ES, Straus DJ, Teruya-Feldstein J, et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodefciency virus-associated Burkitt lymphoma. Cancer. 2003;98(6):1196–1205.
23. Oriol A, Ribera JM, Esteve J, et al. Lack of infuence of human immunodefciency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. Haematologica. 2003;88(4):445–453.
24. Galicier L, Fieschi C, Borie R, et al. Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/ leukemia: a prospective study. Blood. 2007;110(8):2846–2854.
25. Rudek MA, Moore PC, Mitsuyasu RT, et al. A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodefciency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061. Cancer. 2014;120(8): 1194–1202.
26. Okuma Y, Tanuma J, Otera H, et al. 1567PA multi-institutional surveillance of clinicopathological features and molecular epidemiology of egfr mutations in lung cancer patients living with human immunodef-ciency virus infection in Japan. Annals of Oncology. 2014;25(Suppl 4): iv545.